Amgen (AMGN) Tops Q1 EPS by 30c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amgen (AMGN) Posts Solid Q1, All Eyes Now on Repatha CV Outcomes Trial - BMO Capital
April 29, 2016 7:57 AM EDTBMO Capital analyst M. Ian Somaiya reiterated an Outperform rating and raised his price target on Amgen (NASDAQ: AMGN) to $186.00 (from $183.00). He notes while results were solid all eyes will be on the upcoming Repatha CV outcomes trial.
Somaiya commented, "AMGN... More
Amgen (AMGN) PT Raised to $186 at Leerink Partners
April 29, 2016 6:58 AM EDTLeerink Partners analyst Geoffrey Porges raised his price target on Amgen (NASDAQ: AMGN) to $186.00 (from $179.00) following solid Q1 results but stopped short of upgrading the stock and maintained an Market Perform rating.
Porges commented, "Revenue of $5.527bn handily beat consensus by 5%, although it fell short of our estimate of $5.66bn by 2% (Exhibit 1). The main drivers of the revenue... More
